These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2053636)

  • 41. Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results.
    Cucchia AT; Monnat M; Spagnoli J; Ferrero F; Bertschy G
    Drug Alcohol Depend; 1998 Nov; 52(3):243-50. PubMed ID: 9839150
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methadone maintenance treatment: the need to distinguish between holding dose, dose adequacy, satisfaction with methadone as a medication, and satisfaction with treatment.
    Trujols J; Siñol N; de los Cobos JP
    J Clin Psychopharmacol; 2010 Feb; 30(1):95-6; author reply 96. PubMed ID: 20075667
    [No Abstract]   [Full Text] [Related]  

  • 43. Acute physical dependence in man: repeated naloxone-precipitated withdrawal after a single dose of methadone.
    Wright C; Bigelow GE; Stitzer ML
    NIDA Res Monogr; 1989; 95():395-6. PubMed ID: 2701308
    [No Abstract]   [Full Text] [Related]  

  • 44. Limit setting on drug abuse in methadone maintenance patients.
    McCarthy JJ; Borders OT
    Am J Psychiatry; 1985 Dec; 142(12):1419-23. PubMed ID: 4073304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current pharmacotherapies for opioid dependence.
    Kosten TR
    Psychopharmacol Bull; 1990; 26(1):69-74. PubMed ID: 2196628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A trial of methadone tapering schedules in pediatric intensive care unit patients exposed to prolonged sedative infusions.
    Bowens CD; Thompson JA; Thompson MT; Breitzka RL; Thompson DG; Sheeran PW
    Pediatr Crit Care Med; 2011 Sep; 12(5):504-11. PubMed ID: 21076361
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Opioid overdose prevention with intranasal naloxone among people who take methadone.
    Walley AY; Doe-Simkins M; Quinn E; Pierce C; Xuan Z; Ozonoff A
    J Subst Abuse Treat; 2013 Feb; 44(2):241-7. PubMed ID: 22980450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Naltrexone in methadone maintenance patients electing to become "drug free".
    Haas N; Ling W; Holmes E; Blakis M; Litaker M
    NIDA Res Monogr; 1976 Sep; (9):70-3. PubMed ID: 794723
    [No Abstract]   [Full Text] [Related]  

  • 49. Self-regulated opioid detoxification by humans: effects of methadone pretreatment.
    McLeod DR; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1982 Apr; 41():232-8. PubMed ID: 6811914
    [No Abstract]   [Full Text] [Related]  

  • 50. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.
    Renzelli CM; Capretto NA
    J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A double-blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow-release oral morphine versus methadone in opioid-dependent in-patients willing to undergo detoxification.
    Madlung-Kratzer E; Spitzer B; Brosch R; Dunkel D; Haring C
    Addiction; 2009 Sep; 104(9):1549-57. PubMed ID: 19686525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [No opiates against cannabis hyperemesis syndrome].
    Bonnet U; Stratmann U; Isbruch K
    Dtsch Med Wochenschr; 2014 Feb; 139(8):375-7. PubMed ID: 24519114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Methadone detoxification: effects of methadone dose versus time in treatment.
    McCaul ME; Stitzer ML; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1984 Mar; 49():269-74. PubMed ID: 6434971
    [No Abstract]   [Full Text] [Related]  

  • 54. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
    McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
    Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Levo-Alpha Acetyl Methadol (LAAM). Its advantages and drawbacks.
    Finn P; Wilcock K
    J Subst Abuse Treat; 1997; 14(6):559-64. PubMed ID: 9437627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification.
    Preston KL; Bigelow GE; Liebson IA
    Clin Pharmacol Ther; 1985 Aug; 38(2):219-27. PubMed ID: 2410178
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drugs of abuse--opiates.
    Ling W; Wesson DR
    West J Med; 1990 May; 152(5):565-72. PubMed ID: 2161588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical experiences with naltrexone in 370 detoxified addicts.
    Thomas M; Kauders F; Harris M; Cooperstein J; Hough G; Resnick R
    NIDA Res Monogr; 1976 Sep; (9):88-92. PubMed ID: 794726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical experience with antagonist-induced opiate withdrawal under anaesthesia.
    Tretter F; Burkhardt D; Bussello-Spieth B; Reiss J; Walcher S; Büchele W
    Addiction; 1998 Feb; 93(2):269-75. PubMed ID: 9624727
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Endorphin levels in opioid-dependent human subjects: a longitudinal study.
    O'Brien CP; Terenius L; Wahlström A; McLellan AT; Krivoy W
    Ann N Y Acad Sci; 1982; 398():377-87. PubMed ID: 6961864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.